The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
HER2 Subtype Offers Clues for Individualizing Breast Cancer Care
January 29th 2016One-third of patients previously identified as having HER2-positive breast cancer were found to also have a luminal subtype that was resistant to chemotherapy and trastuzumab but still sensitive to the triplet neoadjuvant regimen of pertuzumab, trastuzumab, and chemotherapy.
Dr. Blackwell on Margetuximab for HER2+ Breast Cancer
January 19th 2016Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses the mechanism of action for margetuximab (MGAH22-01) and discusses its potential as a treatment of patients with HER2-positive breast cancer.
Prophylactic Loperamide Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer
Grade 3 diarrhea occurred in 16% of patients treated with neratinib and prophylactic loperamide, representing a significant reduction compared with phase III findings from the ExteNET trial.
T-DM1 Extends Survival in Heavily Pretreated HER2+ Breast Cancer
December 11th 2015T-DM1 (ado-trastuzumab emtansine; Kadcyla) reduced the risk of death by 32% and improved median overall surviva by almost 7 months compared with physician's choice of therapy in heavily pretreated patients with HER2-positive advanced breast cancer.
Dr. Kolberg on Cost-Effectiveness of Pertuzumab in HER2-Positive Breast Cancer
December 10th 2015Hans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses the cost-effectiveness of pertuzumab as a treatment for patients with HER2-positive breast cancer, based off of findings from a study published in the Journal of Clinical Oncology.
Dr. Whitworth on the Importance of Additional HER2 Subtyping
December 10th 2015Pat Whitworth, MD, medical oncologist at the Nashville Breast Center, discusses the prospective neo-adjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.
Prophylactic Intervention Improves Cardiac Safety in HER2-Positive Breast Cancer
Prophylactic administration of standard heart failure medications helped preserve left ventricular ejection fraction in patients treated with trastuzumab for HER2-positive metastatic breast cancer.
HER2-Enriched Molecular Subgroup Highly Sensitive to Breast Cancer Regimens
November 24th 2015The primary analysis of the phase III CALGB 40601 trial found that pathologic complete response to dual HER2 blockade was not statistically higher than anti-HER2 monotherapy. However, there was a high level of intertumoral heterogeneity, and patients with the HER2-enriched subtype had a high pCR with both single and dual anti-HER2 therapy.
Dr. Hudis on Neoadjuvant Treatment of HER2-Positive Breast Cancer
November 23rd 2015Clifford A. Hudis, MD, FACP, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, takes a deeper look at neoadjuvant treatment for patients with HER2-positive breast cancer.
Long-Term Data Support Neoadjuvant Chemo Regimen in HER2+ Breast Cancer
October 20th 2015Hans-Christian Kolberg, MD, discusses updated results from a study that showed that neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab demonstrated significant overall survival and disease-free survival activity in patients with HER2-positive early-stage breast cancer.
Adjuvant HER2+ Breast Cancer Care Evolves, But Questions Remain
October 9th 2015Mohammad Jahanzeb, MD, discusses therapeutic agents that may fit into the adjuvant setting treatment paradigm for HER2-positive breast cancer, the increasing importance of genomic testing, and individualized treatments as multiple agents emerge.
Slamon Explores Evolution of HER2-Positive Breast Cancer Treatment
September 21st 2015Dennis J. Slamon, MD, PhD, discusses the impact of the ADAPT and BOLERO trials and how the increased focus on neoadjuvant therapy with trastuzumab and T-DM1 could transform the treatment of HER2-positive breast cancer.
Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast Cancer
September 14th 2015Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial, which examined T-DM1 in patients with HER2-positive, HR-positive early-stage breast cancer.
Case Study Shows Early Efficacy for Neratinib in HER2-Mutated Metastatic Breast Cancer
Treatment with the second-generation HER2/EGFR-targeted TKI neratinib resulted in a partial response and dramatic improvement in functional status for a patient with HER2-mutated breast cancer.